颈动脉血运重建后行冠状动脉旁路移植术的中期结果
单中心回顾性研究纳入245例在CABG前90天内行颈动脉血运重建的患者,比较联合CEA-CABG与分期CAS-CABG的中期结局。两组在全因死亡、卒中、心肌梗死及复合终点上均无统计学显著差异。
要点
- 联合CEA-CABG与分期CAS-CABG的中期死亡、卒中、心梗风险相似。
- 颈动脉血运重建对合并颈动脉与心脏疾病患者安全有效。
- 本研究为单中心回顾性分析,缺乏随机对照证据。
核心结论
- 颈动脉血运重建是合并颈动脉与心脏疾病患者安全有效的治疗。
- 联合CEA-CABG与分期CAS-CABG的中期死亡、卒中或心梗风险相似。
研究设计与样本
- 单中心回顾性研究,2011年1月至2016年12月纳入245例CABG前90天内行颈动脉血运重建的患者。
- 32例接受联合CEA-CABG,208例接受分期CAS后CABG,5例接受颈动脉支架与冠脉手术杂交。
- 采用多变量logistic回归和倾向评分校正多相风险函数模型分析。
主要发现
- 联合CEA-CABG组1例(3.13%)在CABG术后6个月死亡。
- 分期CAS组9例(4.33%)在CABG术后死亡,其中30天内3例、1年内2例、1年后4例。
关键数值与推荐
- 主要复合终点为全因死亡、卒中和心肌梗死。
- 中期死亡、卒中、心梗及复合事件发生率组间无统计学显著差异。
临床怎么用
- 合并严重颈动脉与冠状动脉疾病时,联合CEA-CABG或分期CAS-CABG均可考虑。
- 两种策略的中期死亡、卒中、心梗风险相似,选择可基于患者个体情况。
局限性
- 单中心回顾性研究,缺乏随机对照设计。
- 杂交组样本量仅5例,未单独比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the absence of randomized trials, the optimal approach to managing coexisting severe carotid and coronary diseases remains controversial. The aim of this study was to present the midterm follow-up results of patients who received a coronary artery bypass graft (CABG) after carotid revascularization and to compare the risk-adjusted outcomes of two approaches to carotid revascularization in the CABG population in a single center. METHODS: From January 2011 to December 2016, 245 patients underwent carotid revascularization within 90 days before CABG in Fuwai Hospital, including 32 who received combined carotid endarterectomy (CEA) and CABG (CEA-CABG), 208 who received staged carotid artery stenting (CAS) before CABG (CAS before CABG), and 5 who underwent a hybrid procedure of carotid stenting and coronary surgery (combined CAS-CABG). The primary composite end points were all-cause death, stroke, and myocardial infarction (MI). Therefore, the multivariable logistic regression analyses and propensity score-adjusted multiphase hazard function model were used to analyze the association between the types of revascularization, complications, and risk-adjusted mortality. RESULTS: One patient (3.13%) died 6 months after the CABG surgery in the combined CEA-CABG group. In the staged CAS group, 9 patients (4.33%) died after CABG surgery, including 3, 2, and 4 patients who died within 30 days, 1 year, and after 1 year (mean time after CABG surgery, 39 months; adjusted odds ratio [OR], 2.188; 95% confidence interval [CI], 0.251-19.093; P = .479), respectively. Stroke was observed in three patients (9.38%) in the combined CEA group and in 12 patients (5.77%) in the staged CAS group (OR, 0.625; 95% CI, 0.133-2.935; P = .552). The rates of MI were 6.25% and 7.21% for the combined and staged groups, respectively (adjusted OR, 1.249; 95% CI, 0.250-6.324; P = .787). In addition, composite events occurred in five (15.63%) and 33 patients (15.87%) in the combined and staged groups, respectively (adjusted OR, 1.362, 95% CI, 0.455-4.077; P = .581). No statistically significant differences were observed in the overall midterm incidences of mortality, stroke, MI, and composite events. CONCLUSIONS: Carotid revascularization is a safe and effective treatment for patients with concomitant carotid and cardiac disease. Combined CEA-CABG and staged CAS-CABG are associated with similar risks of mortality, stroke, or MI in the midterm outcomes.
引用
- Xiang B, Luo X, Yang Y, et al. Midterm results of coronary artery bypass graft surgery after synchronous or staged carotid revascularization. J Vasc Surg. 2019. PMID: 31153704. doi:10.1016/j.jvs.2019.02.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。